Deferasirox Dispersible 250mg Tablet

Owing to the rich industrial experience and expertise in this business, we are involved in manufacturing, exporting and supplying of Deferasirox Dispersible 250mg Tablet in Hyderabad, Telangana, India.

Across a range of anemias, unlock the benefits of once-daily oral DefraTajAR in treating chronic iron overload

DefraTaj (deferasirox) binds to iron and removes it from the blood stream. DefraTajis used to treat iron overload caused by blood transfusions in adults and children at least 2 years old.
DefraTaj is a tridentate ligand that binds iron with high affinity, forming a 2:1 complex that is excreted in bile and eliminated primarily via the feces.
DefraTaj is indicated for the treatment of chronic iron overload due to frequent blood transfusions (a Y7 ml/kg/month of packed red blood cells) in patients with beta thalassemia major aged 6 years and older.

DefraTaj is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:

In patients with beta thalassemia major with iron overload due to frequent blood transfusions (a Y7 ml/kg/month of packed red blood cells) aged 2 to 5 years in patients with beta thalassemia major with iron overload due to infrequent blood transfusions (<7 ml/kg/month of packed red blood cells) aged 2 years and older in patients with other anemias aged 2 years and older

DefraTaj is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with nona transfusiona dependent thalassemia syndromes aged 10 years and older.

Contraindications:

DefraTaj is contraindicated in:
Patients with hypersensitivity to the active substance or the following excipients: lactose monohydrate; crospovidone type A; cellulose, microcrystalline; povidone; sodium lauryl sulfate; silica, colloidal anhydrous; magnesium stearate combination with other iron chelator therapies as the safety of such combinations has not been established patients with estimated creatinine clearance <60 ml/min

Warning
Data in children with NTDT are very limited. As a consequence, DefraTaj therapy should be closely monitored to detect side effects and to follow iron burden in the pediatric population. In addition, before treating heavily iron-overloaded children with NTDT with DefraTaj, the physician should be aware that the consequences of long-term exposure in such patients are currently not known.
Starting DefraTajAR treatment in NTDT patients with chronic iron overload

Measure iron overload with liver iron concentration (LIC)
LIC is the preferred method of iron overload determination and should be used wherever available. Caution should be taken during chelation therapy to minimize the risk of over chelation in all patients.
One course of treatment with DefraTaj is recommended for patients with NTDT who achieve a satisfactory iron level.

Measure iron overload with liver iron concentration (LIC)
LIC is the preferred method of iron overload determination and should be used wherever available. Caution should be taken during chelation therapy to minimize the risk of over chelation in all patients.

One course of treatment with DefraTaj is recommended for patients with NTDT who achieve a satisfactory iron level.

What is DefraTaj?

DefraTaj (deferasirox) binds to iron and removes it from the blood stream. DefraTaj is used to treat iron overload caused by blood transfusions in adults and children at least 2 years old. DefraTaj is also used to treat chronic iron overload syndrome caused by a genetic blood disorder in adults and children who are at least 10 years old.

Important information
You should not use DefraTajif you have severe kidney or liver disease, advanced cancer, a blood cell or bone marrow disorder, or low levels of platelets in your blood.